bplist00—_WebMainResource’	
_WebResourceMIMEType_WebResourceTextEncodingName^WebResourceURL_WebResourceFrameName_WebResourceDataYtext/htmlUUTF-8_Qhttps://www.sec.gov/Archives/edgar/data/1346830/000119312519158835/d753179d8k.htmPOl%<html><head></head><body bgcolor="WHITE"><document>
<type>8-K
<sequence>1
<filename>d753179d8k.htm
<description>8-K
<text>

<title>8-K</title>

 


<center><div style="width:8.5in" align="left">
 <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</p>
<p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" align="center"><b>UNITED STATES </b></p>
<p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" align="center"><b>SECURITIES AND EXCHANGE COMMISSION </b></p>
<p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" align="center"><b>Washington, D.C. 20549 </b></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</p><center>
<p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</p></center> <p style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" align="center"><b>FORM <font style="white-space:nowrap">8-K</font> </b></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</p><center>
<p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</p></center> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" align="center"><b>CURRENT
REPORT </b></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" align="center"><b>Pursuant to Section&nbsp;13 OR 15(d) </b></p>
<p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" align="center"><b>of The Securities Exchange Act of 1934 </b></p>
<p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" align="center"><b>Date of Report (Date of earliest event reported): May&nbsp;29, 2019 </b></p>
<p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</p><center> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</p></center>
<p style="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" align="center"><b>CARA THERAPEUTICS, INC. </b></p>
<p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" align="center"><b>(Exact name of registrant as specified in its charter) </b></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</p><center>
<p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</p></center> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</p>
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" align="center">


<tbody><tr>
<td width="34%"></td>
<td valign="bottom"></td>
<td width="32%"></td>
<td valign="bottom" width="1%"></td>
<td width="32%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top" align="center"><b>Delaware</b></td>
<td valign="bottom">&nbsp;</td>
<td valign="top" align="center"><b><font style="white-space:nowrap">001-36279</font></b></td>
<td valign="bottom">&nbsp;</td>
<td valign="top" align="center"><b><font style="white-space:nowrap">75-3175693</font></b></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td valign="top" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" align="center"><b>(State or other jurisdiction</b></p>
<p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" align="center"><b>of incorporation)</b></p></td>
<td valign="bottom">&nbsp;</td>
<td valign="top" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" align="center"><b>(Commission</b></p>
<p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" align="center"><b>File Number)</b></p></td>
<td valign="bottom">&nbsp;</td>
<td valign="top" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" align="center"><b>(IRS Employer</b></p>
<p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" align="center"><b>Identification No.)</b></p></td></tr>
<tr style="font-size:1pt">
<td height="16" colspan="3"></td>
<td height="16" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="bottom" colspan="3" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" align="center"><b>4 Stamford Plaza</b></p>
<p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" align="center"><b>107 Elm Street, 9<sup style="font-size:85%; vertical-align:top">th</sup> Floor</b></p>
<p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" align="center"><b>Stamford, Connecticut</b></p></td>
<td valign="bottom">&nbsp;</td>
<td valign="bottom" align="center"><b>06902</b></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td valign="top" colspan="3" align="center"><b>(Address of principal executive offices)</b></td>
<td valign="bottom">&nbsp;</td>
<td valign="top" align="center"><b>(Zip Code)</b></td></tr>
</tbody></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" align="center"><b>Registrant‚Äôs telephone number, including area code: (203)
<font style="white-space:nowrap">406-3700</font> </b></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</p><center>
<p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</p></center> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form <font style="white-space:nowrap">8-K</font> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<i>see </i>General Instruction A.2.): </p>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%">
<tbody><tr style="page-break-inside:avoid">
<td width="4%" valign="top" align="left">‚òê</td>
<td align="left" valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " align="left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </p></td></tr></tbody></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%">
<tbody><tr style="page-break-inside:avoid">
<td width="4%" valign="top" align="left">‚òê</td>
<td align="left" valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " align="left">Soliciting material pursuant to Rule <font style="white-space:nowrap">14a-12</font> under the Exchange Act (17
CFR <font style="white-space:nowrap">240.14a-12)</font> </p></td></tr></tbody></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%">
<tbody><tr style="page-break-inside:avoid">
<td width="4%" valign="top" align="left">‚òê</td>
<td align="left" valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " align="left"><font style="white-space:nowrap">Pre-commencement</font> communications pursuant to Rule <font style="white-space:nowrap">14d-2(b)</font> under the Exchange Act (17 CFR <font style="white-space:nowrap">240.14d-2(b))</font> </p></td></tr></tbody></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%">
<tbody><tr style="page-break-inside:avoid">
<td width="4%" valign="top" align="left">‚òê</td>
<td align="left" valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " align="left"><font style="white-space:nowrap">Pre-commencement</font> communications pursuant to Rule <font style="white-space:nowrap">13e-4(c)</font> under the Exchange Act (17 CFR <font style="white-space:nowrap">240.13e-4(c))</font> </p></td></tr></tbody></table>
<p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&nbsp;12(b) of the Act: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</p>
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" align="center">


<tbody><tr>
<td width="34%"></td>
<td valign="bottom"></td>
<td width="32%"></td>
<td valign="bottom" width="1%"></td>
<td width="32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td valign="bottom" nowrap="" align="center" style="border-bottom:1.00pt solid #000000"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" align="center"><b>Title of each class</b></p></td>
<td valign="bottom">&nbsp;</td>
<td valign="bottom" align="center" style="border-bottom:1.00pt solid #000000"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" align="center"><b>Trading</b></p>
<p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" align="center"><b>Symbol(s)</b></p></td>
<td valign="bottom">&nbsp;</td>
<td valign="bottom" align="center" style="border-bottom:1.00pt solid #000000"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" align="center"><b>Name of each exchange</b></p>
<p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" align="center"><b>on which registered</b></p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top" align="center"><b>Common stock, par value $0.001 per share</b></td>
<td valign="bottom">&nbsp;</td>
<td valign="top" align="center"><b>CARA</b></td>
<td valign="bottom">&nbsp;</td>
<td valign="top" align="center"><b>The Nasdaq Stock Market LLC</b></td></tr>
</tbody></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (¬ß230.405 of this chapter) or Rule <font style="white-space:nowrap">12b-2</font> of the Securities Exchange Act of 1934 <font style="white-space:nowrap">(¬ß240.12b-2</font> of this chapter). </p>
<p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" align="right">Emerging growth company&nbsp;&nbsp;‚òí&nbsp;&nbsp;&nbsp;&nbsp; </p>
<p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange Act.&nbsp;&nbsp;‚òí </p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</p>
<p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</p>
</div></center>


<p style="page-break-before:always">
</p><hr size="3" style="COLOR:#999999" width="100%" align="CENTER">


<center><div style="width:8.5in" align="left">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%">
<tbody><tr style="page-break-inside:avoid">
<td width="12%" valign="top" align="left"><b>Item&nbsp;7.01</b></td>
<td align="left" valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " align="left"><b>Regulation FD Disclosure. </b></p></td></tr></tbody></table>
<p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;29, 2019, Cara Therapeutics, Inc. (the ‚ÄúCompany‚Äù) issued a press release announcing
<font style="white-space:nowrap">top-line</font> data from its <font style="white-space:nowrap">KALM-1</font> trial, a multicenter, randomized, double-blind, placebo controlled Phase 3 trial in the United States, evaluating the safety and efficacy
of KORSUVA injection in hemodialysis patients with <font style="white-space:nowrap"><font style="white-space:nowrap">moderate-to-severe</font></font> pruritus. The Company will hold a conference call to discuss the results at 8:30 a.m. EDT on
May&nbsp;29, 2019. A copy of the press release and the presentation to be discussed on the conference call are furnished as Exhibit 99.1 and Exhibit 99.2, respectively, to this Current Report on Form <font style="white-space:nowrap">8-K</font> and
incorporated herein by reference. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information furnished under this Item 7.01, including Exhibit 99.1 and Exhibit 99.2, shall not be
deemed ‚Äúfiled‚Äù for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section. The information shall not be deemed incorporated by reference into any other filing with the
Securities and Exchange Commission made by the Company, regardless of any general incorporation language in such filing. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%">
<tbody><tr style="page-break-inside:avoid">
<td width="12%" valign="top" align="left"><b>Item&nbsp;8.01</b></td>
<td align="left" valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " align="left"><b>Other Information. </b></p></td></tr></tbody></table>
<p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;29, 2019, the Company issued a press release announcing <font style="white-space:nowrap">top-line</font> data from its <font style="white-space:nowrap">KALM-1</font> trial, a multicenter, randomized, double-blind, placebo controlled Phase 3 trial in the United States, evaluating the safety and efficacy of KORSUVA injection in hemodialysis patients with <font style="white-space:nowrap"><font style="white-space:nowrap">moderate-to-severe</font></font> pruritus. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b><font style="white-space:nowrap">KALM-1</font>
Phase 3 Trial Design </b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <font style="white-space:nowrap">KALM-1</font> Phase 3 U.S. trial is a multicenter, randomized, double-blind,
placebo-controlled <font style="white-space:nowrap">12-week</font> treatment trial with a <font style="white-space:nowrap">52-week</font> open label extension phase that is designed to evaluate the safety and efficacy of 0.5&nbsp;mcg/kg KORSUVA
(CR845/difelikefalin) injection in 350 hemodialysis patients with <font style="white-space:nowrap"><font style="white-space:nowrap">moderate-to-severe</font></font> pruritus. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary efficacy endpoint is the proportion of patients achieving at least a <font style="white-space:nowrap">three-point</font>
improvement from baseline in the weekly mean of the daily <font style="white-space:nowrap">24-hour</font> Worst Itch Numeric Rating Scale <font style="white-space:nowrap">(WI-NRS)</font> score at week&nbsp;12. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Secondary endpoints include assessment of itch-related quality of life changes measured using the validated self-assessment <font style="white-space:nowrap">5-D</font> itch and <font style="white-space:nowrap">Skindex-10</font> scales, as well as the proportion of patients achieving <font style="FONT-FAMILY:SYMBOL">¬≥</font> four-point improvement from baseline in weekly
mean of the daily <font style="white-space:nowrap">24-hour</font> <font style="white-space:nowrap">WI-NRS</font> score at week<u></u>&nbsp;12. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b><font style="white-space:nowrap">KALM-1</font> Efficacy Data: </b></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%">
<tbody><tr style="page-break-inside:avoid">
<td width="1%">&nbsp;</td>
<td width="2%" valign="top" align="left">‚Ä¢</td>
<td width="1%" valign="top">&nbsp;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><u></u><i>Primary Endpoint</i>: The proportion of patients receiving 0.5mcg/kg of KORSUVA injection achieving a <font style="FONT-FAMILY:SYMBOL">¬≥</font> three-point improvement from baseline in the weekly mean of the daily <font style="white-space:nowrap">24-hour</font> <font style="white-space:nowrap">WI-NRS</font> score at week 12 was 51%, compared to 28%
for patients receiving placebo (p= 0.000019). </p></td></tr></tbody></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%">
<tbody><tr style="page-break-inside:avoid">
<td width="1%">&nbsp;</td>
<td width="2%" valign="top" align="left">‚Ä¢</td>
<td width="1%" valign="top">&nbsp;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><i>Secondary Endpoints</i>: </p></td></tr></tbody></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%">
<tbody><tr style="page-break-inside:avoid">
<td width="5%">&nbsp;</td>
<td width="2%" valign="top" align="left">‚Ä¢</td>
<td width="1%" valign="top">&nbsp;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><i><font style="white-space:nowrap">4-point</font> Improvement from baseline in
<font style="white-space:nowrap">24-hour</font> <font style="white-space:nowrap">WI-NRS</font> score</i>. The proportion of patients receiving 0.5mcg/kg of KORSUVA injection achieving a <font style="FONT-FAMILY:SYMBOL">¬≥</font> four-point
improvement from baseline in the weekly mean of the daily 24 hour <font style="white-space:nowrap">WI-NRS</font> score at week 12 was 39%, compared to 18% for patients receiving placebo (p= 0.000032). </p></td></tr></tbody></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%">
<tbody><tr style="page-break-inside:avoid">
<td width="5%">&nbsp;</td>
<td width="2%" valign="top" align="left">‚Ä¢</td>
<td width="1%" valign="top">&nbsp;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><i>Itch-Related Quality of Life Measures</i>: </p></td></tr></tbody></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%">
<tbody><tr style="page-break-inside:avoid">
<td width="9%">&nbsp;</td>
<td width="3%" valign="top" align="left">‚Ä¢</td>
<td width="1%" valign="top">&nbsp;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Patients receiving KORSUVA injection experienced a 43% improvement in the average total <font style="white-space:nowrap">Skindex-10</font> score at week 12, compared to patients receiving placebo (p= 0.0004). </p></td></tr></tbody></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%">
<tbody><tr style="page-break-inside:avoid">
<td width="9%">&nbsp;</td>
<td width="3%" valign="top" align="left">‚Ä¢</td>
<td width="1%" valign="top">&nbsp;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><u></u>Patients receiving KORSUVA injection experienced a 35% improvement in the average total <font style="white-space:nowrap">5-D</font> Itch score at week 12, compared to patients receiving placebo (p= 0.0009). </p></td></tr></tbody></table>
</div></center>


<p style="page-break-before:always">
</p><hr size="3" style="COLOR:#999999" width="100%" align="CENTER">


<center><div style="width:8.5in" align="left">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b><font style="white-space:nowrap">KALM-1</font> Safety and Tolerability: </b></p>
<p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">KORSUVA was generally well-tolerated with a safety profile consistent with that seen in earlier KORSUVA clinical trials. Overall, the incidence
of adverse events (‚ÄúAEs‚Äù) and serious AEs were similar across both KORSUVA and placebo groups. The most common treatment emergent AEs reported in <font style="FONT-FAMILY:SYMBOL">¬≥</font> 5% patients were diarrhea (9.5% KORSUVA vs.
3.7% placebo), dizziness (6.9% KORSUVA vs. 1.1% placebo), nasopharyngitis (KORSUVA 5.3% vs. 3.2% placebo) and vomiting (5.3% KORSUVA vs. 3.2% placebo). </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%">
<tbody><tr style="page-break-inside:avoid">
<td width="12%" valign="top" align="left"><b>Item&nbsp;9.01</b></td>
<td align="left" valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " align="left"><b>Financial Statements and Exhibits. </b></p></td></tr></tbody></table>
<p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</p>
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">


<tbody><tr>
<td></td>
<td valign="bottom" width="5%"></td>
<td width="92%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td valign="bottom" nowrap="" align="center">
<p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " align="center"><b>Exhibit<br>&nbsp;&nbsp;&nbsp;&nbsp;No.&nbsp;&nbsp;&nbsp;&nbsp;</b></p></td>
<td valign="bottom">&nbsp;&nbsp;</td>
<td valign="bottom">&nbsp;</td></tr>


<tr style="font-size:1pt">
<td height="8"></td>
<td height="8" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top" nowrap="">99.1</td>
<td valign="bottom">&nbsp;&nbsp;</td>
<td valign="top"><a href="d753179dex991.htm">Press release dated May&nbsp;29, 2019. </a></td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td height="8" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top" nowrap="">99.2</td>
<td valign="bottom">&nbsp;&nbsp;</td>
<td valign="top"><a href="d753179dex992.htm">Presentation dated May&nbsp;29, 2019. </a></td></tr>
</tbody></table>
</div></center>


<p style="page-break-before:always">
</p><hr size="3" style="COLOR:#999999" width="100%" align="CENTER">


<center><div style="width:8.5in" align="left">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" align="center"><b>SIGNATURES </b></p>
<p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</p><div align="right">
<table cellspacing="0" cellpadding="0" width="40%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<tbody><tr>
<td width="6%"></td>
<td valign="bottom" width="2%"></td>
<td width="92%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top" colspan="3"><b>CARA THERAPEUTICS, INC.</b></td></tr>
<tr style="font-size:1pt">
<td height="16"></td>
<td height="16" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top">By:</td>
<td valign="bottom">&nbsp;</td>
<td valign="bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mani Mohindru</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"></td>
<td valign="bottom">&nbsp;</td>
<td valign="bottom">Mani Mohindru, Ph.D.</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"></td>
<td valign="bottom">&nbsp;</td>
<td valign="bottom">Chief Financial Officer</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"></td>
<td valign="bottom">&nbsp;</td>
<td valign="bottom">(Principal Financial and Accounting Officer)</td></tr>
</tbody></table></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: May&nbsp;29, 2019</p>
</div></center>


</text>
</description></filename></sequence></type></document>
</body></html>    ( > \ k Ç î û § ¯ ˘                           m"